Previous studies in primates have shown that chronic systemic administration of the succinate dehydrogenase (SDH) inhibitor, 3-nitropropionic acid (3NP), replicates most of the motor, cognitive, and histopathological features of Huntington's disease. In the present study, serial 1H-NMR spectroscopy (1H-MRS) assessment of striatal and occipital cortex concentrations of N-acetylaspartate, phosphocreatine/creatine, choline, and lactate, were obtained every 2-weeks during the entire course of a chronic 3NP treatment in baboons. A region-selective increase in lactate was detected in the striatum of the 3NP-treated animals, either immediately before or in conjunction with a lesion in the dorsolateral putamen detected by T2-MR imaging. Absolute 1H-MRS quantitation demonstrated a progressive and region-specific decrease in striatal N-acetylaspartate, creatine, and choline, occuring as early as 3 weeks before the first detection of lactate. These results demonstrate that 1H-MRS can be used to monitor early stages of brain metabolic impairment. In addition, given that 3NP-induced SDH inhibition following systemic injection similarly affects all brain regions, the striatal selective decreases in N-acetylaspartate or creatine concentrations are not simply related to the level of mitochondrial impairment but to a preferential vulnerability of the striatum to 3NP-induced toxicity. 1999 Academic Press
INTRODUCTION
Localized proton magnetic resonance spectroscopy (1H-MRS) makes it possible to study some aspects of brain biochemistry in vivo. It therefore holds great potential for the study of neurological disorders involving neurodegeneration and/or metabolic impairments (Michaelis et al., 1993) . In particular, this method detects signals arising from various brain metabolites such as N-acetylaspartate (NAA), choline-containing compounds (Cho), and phosphocreatine/creatine (Cr) (Miller, 1991) . Whereas NAA is almost exclusively located within neurons in the adult brain and as such is used as a marker of neuronal integrity, the creatine signal measures both creatine and phosphocreatinetwo metabolites involved in cellular (both glial and neuronal) energy metabolism. Even though one might expect that concentrations in these metabolites change in neurodegenerative diseases such as Leigh's disease, Leber's disease, and MELAS (mitochondrial encephalopathy with lactic acidosis and stroke-like episodes) for which energy impairment is directly a causal factor (Wallace, 1992; Johns, 1995) , alterations in these metabolites can also be expected in other neurodegenerative disorders such as Parkinson's, Huntington's, and Alzheimer's diseases (Holshouser et al., 1995; Jenkins et al., 
